1. Late-onset neutropenia following ocrelizumab therapy for multiple sclerosis;Cohen;Neurology,2019
2. Rituximab associated late-onset neutropenia—a rheumatology case series and review of the literature;Monaco;Clin. Rheumatol.,2016
3. Ocrevus full prescibing information, available athttps://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761053lbl.pdf (2017, accessed January 13, 2020).
4. Late-onset neutropenia following rituximab therapy: incidence, clinical features and possible mechanisms;Tesfa;Exp. Rev. Hematol.,2011
5. Late onset absolute neutropenia associated with ocrelizumab treatment in multiple sclerosis: a case report and review of the literature;Zanetta;J. Neurol. Sci.,2019